Back to medical news
MedPage Today
Subcutaneous Risankizumab Induction Improved Outcomes in Crohn's Disease
October 16, 2026
Original source summary
(MedPage Today) -- Subcutaneous risankizumab (Skyrizi) induction therapy significantly improved clinical remission and endoscopic response rates in patients with moderately to severely active Crohn's disease, results from the phase III AFFIRM trial...
Verbatim from MedPage Today's own feed — "Subcutaneous Risankizumab Induction Improved Outcomes in Crohn's Disease"
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
More medical news